# RANBP2

Source: https://onco.cc/targets/ranbp2/  
OnCo record `ranbp2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RANBP2 (E3 SUMO-protein ligase RanBP2) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Hepatocellular carcinoma, Renal cell carcinoma and 5 more.

## Summary

E3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates. Binds single-stranded RNA (in vitro).

Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.85, affected pathway 0.76, genetic association 0.10, somatic mutation 0.94). IntOGen calls it a driver in 7 cohorts (1 activating, 5 loss-of-function), covering Renal Clear Cell Carcinoma, Hepatocellular Carcinoma, Lung Squamous Cell Carcinoma, Neuroblastoma, Paraganglioma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: RAN binding protein 2; E3 SUMO-protein ligase RanBP2; NUP358; ADANE; ANE1
- Tags: cancer-genes-wave
- Symbol: RANBP2
- Class: enzyme
- Biology: E3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates. Binds single-stranded RNA (in vitro). May bind DNA. Component of the nuclear export pathway. Specific docking site for the nuclear export factor exportin-1. Location: Nucleus; Nucleus membrane; Nucleus, nuclear pore complex; Nucleus envelope (UniProt). Locus 2q13 (HGNC).
- Where found: Lung cancer: Open Targets association 0.59 with lung cancer (MONDO_0008903); Hepatocellular carcinoma: IntOGen driver in 2 cohorts (HCC); Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC); Pheochromocytoma and paraganglioma: IntOGen driver in 1 cohort (PGNG); Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898); Breast cancer: Open Targets association 0.52 with breast cancer (MONDO_0007254)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9848: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9848
- UniProt P49792: https://www.uniprot.org/uniprotkb/P49792/entry
- NCBI Gene 5903: https://www.ncbi.nlm.nih.gov/gene/5903
- Ensembl ENSG00000153201: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000153201

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Clear cell renal cell carcinoma](https://onco.cc/cancers/clear-cell-rcc/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pheochromocytoma and paraganglioma (PPGL)](https://onco.cc/cancers/pheochromocytoma-paraganglioma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/ranbp2.json